Related Experiment Video

Updated: Oct 3, 2025

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

1.7K

Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors

Gabriela Reyes-Castellanos1, Nadine Abdel Hadi1, Alice Carrier1

  • 1Centre de Recherche en Cancérologie de Marseille (CRCM), CNRS, INSERM, Institut Paoli-Calmettes, Aix Marseille Université, F-13009 Marseille, France.

Cells
|February 15, 2022
PubMed

Insights

Metabolic reprogramming fuels cancer growth and therapy resistance, especially in Pancreatic Ductal Adenocarcinoma (PDAC). Targeting autophagy, a key survival process in PDAC, offers a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Cancer Metabolism
  • Molecular Biology

Background:

  • Metabolic reprogramming is a hallmark of cancer, influencing tumor development and treatment resistance.
  • Pancreatic Ductal Adenocarcinoma (PDAC) is notably refractory to therapies, highlighting the need for novel treatment strategies.
  • Autophagy, a cellular recycling process, is frequently dysregulated in PDAC.

Purpose of the Study:

  • To explore the role of metabolic reprogramming and autophagy in Pancreatic Ductal Adenocarcinoma (PDAC).
  • To identify therapeutic vulnerabilities associated with aberrant autophagy in PDAC.
  • To discuss the potential of combining autophagy inhibition with other treatments for PDAC.

Main Methods:

  • Review of current literature on cancer metabolism and autophagy in PDAC.
  • Analysis of the interplay between genetic alterations, mitochondrial metabolism, tumor microenvironment, and immune system in PDAC.
  • Examination of the link between autophagy and therapeutic resistance in PDAC.

Main Results:

  • Autophagy is elevated in established PDAC, supporting proliferation in nutrient-poor conditions.
  • Autophagy contributes to PDAC's resistance to current therapies.
  • Autophagy is interconnected with genetic factors, mitochondrial function, the tumor microenvironment, and immune responses in PDAC.

Conclusions:

  • Targeting autophagy presents a viable strategy for treating PDAC, particularly in combination therapies.
  • Further translational and multidisciplinary research is crucial for optimizing autophagy-targeted treatments for PDAC.
  • Understanding metabolic vulnerabilities, including autophagy, is key to overcoming therapeutic resistance in PDAC.
Keywords:
autophagycancer metabolismmitochondrial metabolismpancreatic ductal adenocarcinomatherapeutic resistance

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

694
Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches07:04

Author Spotlight: Assessment of Mitophagy Flux in Pancreatic β-Cells Using Effective and Robust Complementary Approaches

Published on: September 15, 2023

1.6K

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
8.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K